Harmony Biosciences announced that the Phase 3 RECONNECT trial of ZYN002 in Fragile X syndrome failed to meet its primary endpoint. The post RECONNECT Trial Results: ZYN002 Does Not Meet Primary Endpoint in Fragile X appeared first on FRAXA Research Foundation - Finding a Cure for Fragile X Syndrome.
